Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol Myers Squibb had its Relative Strength (RS) Rating upgraded from 63 to 79 Tuesday — a welcome improvement, but still ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Application error: a client-side exception has occurred (see the browser console for more information).

Bris­tol My­ers Squibb is lift­ing its 2024 fi­nan­cial guid­ance for the sec­ond straight quar­ter as CEO Chris Boern­er’s “tran­si­tion pe­ri­od” con­tin­ues.

Investing.com -- Bristol-Myers Squibb (NYSE:BMY) raised its full-year earnings guidance as the company’s Q3 results handily beat expectations. The company’s shares rose more than 2% in ...

(RTTNews) - Bristol-Myers Squibb Co. (BMY) announced earnings for third quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $1.211 billion ...